Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Amgen (AMGN) has demonstrated strong recent performance, with its shares gaining 10.6% over the past month, significantly outpacing the S&P 500's 4.9% return. The biotech giant has consistently beaten consensus earnings and revenue estimates, including a 17.79% EPS surprise last quarter. While analysts project continued growth, with current quarter EPS expected to rise 5.6% year-over-year, and the company's Zacks Value Style Score of 'B' suggests it trades at a discount to peers, its Zacks Rank #3 (Hold) indicates a near-term performance in line with the broader market.

Analysis

Amgen has demonstrated significant recent market outperformance, with its shares returning +10.6% over the past month, more than doubling the S&P 500's +4.9% gain. This momentum is underpinned by a strong history of earnings execution, exemplified by the last reported quarter's 17.79% EPS surprise and a consistent record of beating consensus estimates over the past four quarters. Analyst consensus projects continued growth, with current fiscal year EPS and revenue expected to increase by 5.2% and 5.4% respectively. However, the outlook is mixed, as current quarter estimates have seen a slight downward revision of 0.2%, and more notably, projected growth decelerates sharply into the next fiscal year, with EPS growth slowing to 2.2% and revenue growth to 1.7%. Despite this decelerating growth profile, the stock's valuation appears reasonable, with a Zacks Value Style Score of 'B' indicating it trades at a discount to its peers. The overall Zacks Rank #3 (Hold) suggests an expectation of near-term performance in line with the broader market, balancing strong recent results against a more modest forward outlook.

Key Decisions for Investors

• Given the significant recent stock appreciation of +10.6% contrasted with projections for decelerating growth next fiscal year, investors who have benefited from the run-up may consider taking some profits.
• Value-focused investors should note the stock appears to trade at a discount relative to its peers, but must weigh this against the material slowdown in projected revenue and earnings growth for the next fiscal year.
• Monitor upcoming earnings reports for any revisions to corporate guidance, as the current Zacks Rank #3 (Hold) indicates the stock may require new catalysts to sustain its recent outperformance relative to the market.